Struggling OvaScience reorganizes, stock plunges; Chugai inks €130M deal; Ironwood, Allergan report new linaclotide CR2 data
• With its fertility game plan struggling, Waltham, MA-based OvaScience says it will chop out 30% of its staff to help reduce expenses and extend its cash runway. New CEO Harald Stock and COO Paul Chapman are out the door as well, signaling the kind of turmoil that investors hate. The company’s stock $OVAS plunged 29% this morning as founding CEO Michelle Dipp stepped back in to oversee the company as it reorganized and looked for a new CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.